Chirurgia (Bucur). 2013;108(6):849-854

The Significance of PDGF Expression in Serum of Colorectal Carcinoma Patients - Correlation with Dukes Clasification. Can PDGF Become a Potential Biomarker?

C. Braicu[1,2], O. Tudoran[1], L. Balacescu[1], C. Catana[3], E. Neagoe[4], I. Berindan-Neagoe[1,2,5], C. Ionescu[6,7]
[1]Department of Functional Genomics, "Ion Chiricuta" Oncology Institute, Cluj Napoca, Romania
[2]Research Center of Functional Genomics, Biomedicine and Translational Medicine
"Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania
[3]Department of Biochemistry, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania
[4]Department of Surgery, The Oncology Institute "Ion Chiricuta", Cluj Napoca, Romania
[5]Department of Immunology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania
[6]Department of Surgery, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania
[7]Surgery Clinic 1, County Hospital, Cluj Napoca Romania

Abstract
Background: The expression of serum angiogenic factors has been associated with tumor dissemination and poor prognosis in multiple cancer types. However, it is still unclear whether these angiogenic molecules can be used as an independent molecular marker or in correlation with other parameters for predicting the prognosis of colorectal carcinoma (CRC) patients.
Methods: Protein expression was evaluated in 28 CRC and 10 control cases using Angiogenesis Fast Quant technology.
Results: In this study, we found downregulation of PDGF-bb protein expression in the serum of patients with colorectal cancer compared with the control group. Thus, PDGF-bb might play an essential function in the progression of CRC.
Conclusions: Our study indicated that the PDGF-bb protein expression might be an independent prognostic marker or in association with other parameters for CRC patients.
Key words: colorectal cancer, biomarkers, serum protein, PDGF-bb

Corresponding author: Ioana Berindan-Neagoe, MD
Research Center of Functional Genomics
Biomedicine and Translational Medicine
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
E-mail: ioana.neagoe@umfcluj.ro